^
    Back
    Association details:
    Biomarker:HLA-DRB4 expression
    Cancer:Non Small Cell Lung Cancer
    Drug Class:Immunotherapy
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    ASCO 2023
    Title:

    Role of HLA-DRB4 as a biomarker for endocrine toxicity and survival outcomes after immunotherapy in metastatic non-small cell lung cancer.

    Published date:
    05/25/2023
    Excerpt:
    ...improved survival in both univariate (PFS 9.9 months, p = 0.040; OS 26.3 months, p = 0.0085) and MVA (PFS p = 0.0310, HR 0.55, 95% CI [0.31, 0.95]); OS p = 0.003, HR 0.40, 95% CI [0.21, 0.73])….Expression of HLA-DRB4 was associated with the development of endocrine irAEs and correlated with improved survival outcomes in metastatic NSCLC patients being treated with ICIs.
    DOI:
    10.1200/JCO.2023.41.16_suppl.e21005